Clinical Trial Update: Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anti-PD-1 antibody with chidamide and rituximab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Anti-PD-1 antibody
• Chidamide (chidamide)
• Rituximab (rituximab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Relapsed or Refractory DLBCL | Phase 2 | Status: UNKNOWN